Profiles

Dr. William G. Tucker Curriculum Vitae
President
Dr. Tucker completed a three year residency in internal medicine and an additional two years training in haematology and oncology. He then accepted an appointment to the academic teaching faculty in the oncology department of Henry Ford Hospital in Detroit, Michigan. At Henry Ford Hospital he was involved in research and drug development supported by a National Cancer Institute grants. He later accepted the Directorship of the Mid-West Oncology Center in Kalamazoo, Mi. The Mid-West Oncology Center became a member of the Southwest Oncology Group of the National Cancer Institute.

As a Principal Investigator for the National Cancer Institute, he was involved in the early phase development of many oncologic pharmaceutical agents and was the first physician in the U.S. to have Ifostamide for developing the clinical use of the drug for the treatment of cancer patients. As a Principal Investigator for Mead Johnson Pharmaceutical, he developed an effective method of administration of Ftorafur. He was Principal Investigator for the Federal Drug Administration and developed a protocol for brain tumors.

In his research laboratory he developed an oral drug delivery system which on first pass bypasses the liver which allowed considerable increase in serum levels for some pharmaceutical agents. This same system was effective in transdermal passage. The patent ran out years ago but this is the system used by the cosmetic companies for topical retinol palmitate.

Recently, he moved to Prince Edward Island in Canada which is a developing research community with a lot of bright young researchers where his present research is in cancer chemotherapies. At present in development is an agent that crosses the blood brain barrier and effectively destroys primary brain tumors in three months. The tumor cell is destroyed in all phases of the cell cycle including G-o.

Another research project Dr. Tucker has developed is an anti- viral agent that crosses the blood brain barrier and prevents the replication of the measles virus in the cerebral spinal fluid which stabilizes the multiple sclerosis patient from further neurologic progression. The anti-viral drug is effective in preventing replication of the Influenza virus "A" (H1N1) and Influenza "B".

Curriculum Vitae

Vivian Tucker
Vice-President and CFO
Vivian Tucker has a degree in business and foreign languages. In addition to this she has done studies in Business Law and Psychology.

Mrs. Tucker has owned two international businesses. President and CEO of both companies.

Jennifer Londre
Administrative assistant and Researcher

Ms. Londre has a degree in Business with an extensive background in Business Law, Computer Science, and Research.

R. Andrew Paskauskas, PhD, MSc
Senior Consultant
Dr. Paskauskas holds M.A. and Ph.D. degrees in Science and Technology from the University of Toronto, and an M.Sc. in Bioinformatics from the University of Oxford, UK. He is an Elected Member of the New York Academy of Sciences, and has been a Western Societies Fellow at Cornell University.

Possessing a broad range of experience in both the academic and industrial aspects of research and development, Dr. Paskauskas has channeled his interests in critical problem solving and decision-support systems into bioinformatics. His focus is interdisciplinary, and includes issues related to technical computing and software development, parallel computing, algorithm design, interactive multimedia, the biological and chemical sciences, mathematical statistics, chemoinformatics, and drug discovery and development.

Dr. Paskauskas was Chief Scientist, Biomolecular Informatics, for the company between May 2007 and January 2010. He is currently a Senior Consultant to Biomolecular Pharma for drug discovery and development.